Acute pancreatitis in marrow transplant patients: prevalence at autopsy and risk factor analysis.
Pancreatitis has been described as an infrequent complication of marrow transplantation. This study investigated the prevalence of pancreatitis at autopsy in marrow transplant patients and determined risk factors for its development. We reviewed consecutive autopsy reports from 1991 to 1993. Medical records and laboratory reports were reviewed for analysis of clinical variables. Autopsy findings and clinical variables were correlated with the autopsy diagnosis of pancreatitis. Pancreatitis was found in 51 of 184 (28%) patients at autopsy. Of those with pancreatitis, 35% had abdominal pain, 10% had measurements of serum pancreatic enzymes, and 20% had abdominal imaging studies in the week prior to death. By univariable analysis, risk factors associated with development of pancreatitis included clinical grades 3 and 4 GVHD, GVHD at autopsy, liver GVHD at autopsy, major infection at autopsy, and increasing days of survival. By multivariable analysis, independent risk factors for its development included any GVHD at autopsy, increasing length of survival after transplantation, and major infection at autopsy. We conclude that pancreatitis is a common but often subclinical complication of marrow transplantation. Its development may be associated with a high prevalence of biliary sludge and prolonged treatment of GVHD with cyclosporine and prednisone.
Ko
C W
CW
University of Washington School of Medicine, Seattle, USA.
Gooley
T
T
Schoch
H G
HG
Myerson
D
D
Hackman
R C
RC
Shulman
H M
HM
Sale
G E
GE
Lee
S P
SP
McDonald
G B
GB
D015746:Abdominal Pain / Q000453:epidemiology / Q000209:etiology; D000208:Acute Disease; D000328:Adult; D000681:Amylases / Q000097:blood; D001646:Bile / Q000737:chemistry; D015415:Biomarkers; D016026:Bone Marrow Transplantation / Q000009:adverse effects* / Q000401:mortality; D002423:Cause of Death; D015331:Cohort Studies; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D005704:Gallbladder / Q000473:pathology; D006086:Graft vs Host Disease / Q000150:complications / Q000401:mortality; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D009369:Neoplasms / Q000150:complications / Q000628:therapy; D010195:Pancreatitis / Q000453:epidemiology / Q000209:etiology*; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D015995:Prevalence; D012307:Risk Factors; D019172:Transplantation Conditioning / Q000009:adverse effects; D014916:Whole-Body Irradiation / Q000009:adverse effects
D015415:Biomarkers; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D000681:Amylases; D011241:Prednisone; D008727:Methotrexate